Group 1 - Gilead Sciences showcased 13 innovative drugs at the China International Import Expo, emphasizing their commitment to creating a healthier world [1] - The long-acting HIV pre-exposure prophylaxis drug, Lenacapavir, is the first of its kind approved globally, requiring administration only twice a year, and has recently been applied in China [1] - The expo featured numerous cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first rechargeable closed-loop spinal cord stimulation system [1] Group 2 - This year's expo saw an increase in reception and negotiation spaces for pharmaceutical companies, indicating a growing emphasis on business interactions [2] - A centralized signing hall was established for procurement activities, with nearly 200 buyers from central enterprises and health authorities expected to engage in over 70 signing events [2] - The overall theme of the expo is focused on collaboration to create a healthier world through new products, technologies, and services [3]

Group 1 - Gilead Sciences showcased its innovative drug, Lenacapavir, which is the world's first long-acting HIV pre-exposure prophylaxis approved for administration twice a year, recently launched in China [1] - The exhibition highlighted 13 innovative drugs launched by Gilead in China, emphasizing the company's commitment to improving drug accessibility and promoting health equity [1] - The event featured various cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first-ever rechargeable closed-loop spinal cord stimulation system [1][2] Group 2 - This year's exhibition saw an increase in reception and negotiation spaces for pharmaceutical companies, indicating a growing emphasis on business interactions [2] - A centralized signing hall was established for nearly 200 buyers from central enterprises and health authorities to engage in over 70 signing activities with exhibitors [2] - The overarching theme of the event was to collaboratively "create a healthier world," showcasing new products, technologies, and services [3]

Group 1 - Gilead Sciences showcased 13 innovative drugs and projects aimed at improving drug accessibility and promoting health equity at the China International Import Expo [1] - The innovative drug Lenacapavir, a long-acting HIV pre-exposure prophylaxis approved for administration twice a year, has recently been approved in China and completed its first application [1] - The expo featured numerous cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first-ever rechargeable closed-loop spinal cord stimulation system [1] Group 2 - This year's expo saw an increase in reception and negotiation spaces for pharmaceutical companies compared to previous years [2] - A centralized signing hall was established for nearly 200 buyers from central enterprises and health authorities to engage in over 70 signing activities with exhibitors [2] - The overarching theme of the expo is to collaboratively "create a healthier world" through new products, technologies, and services [3]

Group 1: Event Overview - The eighth China International Import Expo (CIIE) is set to open in 50 days, showcasing the vitality of the Chinese market for foreign enterprises [1] - Several long-term exhibitors, referred to as "old friends" of the expo, are preparing to present new innovations and products [1] Group 2: Company Highlights - Schott, a high-tech international group, is integrating natural quartz glass into its special materials matrix, which is crucial for microchip manufacturing [1] - Schott will publicly showcase this technology for the first time in China at the expo, along with other innovative technologies such as glass-metal sealing technology [1] - Medtronic, a long-standing partner of the expo, will present over 100 innovative medical technology products, including the Asia-Pacific debut of its first closed-loop rechargeable spinal cord stimulation system [2] - Medtronic's strategy has evolved from being an exhibitor to an investor, aiming to localize global wisdom and globalize Chinese innovation [2] - Sanofi, also a consistent participant, will focus on groundbreaking innovations in the global immunology field, showcasing breakthrough drugs and vaccines [3] Group 3: Strategic Importance - The CIIE serves as a vital bridge connecting global innovation with the Chinese market, facilitating the transformation of innovations from "imported" to "exported" [2] - Sanofi emphasizes its commitment to the Chinese market as a key engine in its global strategy, aiming to support the development of China's pharmaceutical ecosystem [3]